Rephonic
Artwork for Blood Cancer Talks
Multiple Myeloma
Lymphoma
Clinical Trials
Acute Myeloid Leukemia
Diffuse Large B-Cell Lymphoma
Minimal Residual Disease
Bispecific Antibodies
Daratumumab
Follicular Lymphoma
CAR T-Cell Therapy
Venetoclax
Chronic Myeloid Leukemia
Progression-Free Survival
Mantle Cell Lymphoma
FDA
AL Amyloidosis
Overall Survival
Polycythemia Vera
Belantamab Mafidotin
Tyrosine Kinase Inhibitors

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggesti... more

PublishesMonthlyEpisodes76Founded4 years ago
Number of ListenersCategories
EducationHealth & FitnessMedicine

Listen to this Podcast

Artwork for Blood Cancer Talks

Latest Episodes

Topics Covered

1. KOMET-007 and SNDX-5613-0708: Menin Inhibitors with Intensive Chemotherapy

KOMET-007: Phase 1a/b study adding ziftomenib 600 mg once daily, starting on day 8, to 7+3 induction and continuing it through consolidation, in 99 patient... more

Blood Cancer Talks — Show Notes

Episode: Best of ASCO/EHA 2026 — Multiple Myeloma & AL Amyloidosis

Guest: Dr. Prashant Kapoor, MD Professor of Medicine, Mayo Clinic, Rochester, MN Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo Clinic

E... more

BloodCancerTalks: ASCO/EHA 2026 Lymphoma Round-Up with Dr. Thomas Lew

Guest: Dr. Thomas Lew, Peter MacCallum Cancer Centre (Melbourne, Australia) — hematologist specializing in lymphoid malignancies.

In this episode, we break down the biggest lymph... more

Episode Overview

For the second time in two decades, a phase 3 trial has shown a statistically significant improvement over R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). In this episode, Eddie, Raj, and Ashwin sit down with Profes... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

WolverHeme Happy Hour
WolverHeme Happy HourBernard Marini, Anthony Perissinotti, et al.
Two Onc Docs
Two Onc DocsSam and Karine
Blood Podcast
Blood PodcastAmerican Society of Hematology

Recent Guests

Curtis Lacovitz
Assistant Professor, AML specialist
Oregon Health Sciences University (OHSU)
Episode: Episode 75. ASCO & EHA 2026 Myeloid Roundup with Dr. Joshua Zeidner
Prashant Kapoor
Hematologist; Professor of Medicine and Chair of myeloma, amyloidosis, and dysproteinemia group
Mayo Clinic, Rochester, Minnesota
Episode: Episode 74. Myeloma Updates from ASCO/EHA 2026 with Dr. Prashant Kapoor
Thomas Lew
Hematologist specialized in lymphoid malignancies at Peter MacCallum Cancer Centre; researcher at Walter and Eliza Hall Institute
Peter MacCallum Cancer Centre; Walter and Eliza Hall Institute
Episode: Episode 73. ASCO and EHA 2026 Lymphoma Roundup with Dr. Thomas Lew
Charles Herbaux
Professor of Hematology, University of Montpellier; lymphoma expert
University of Montpellier
Episode: Episode 72. frontMIND Trial in DLBCL with Dr. Charles Herbaux
Vincent Rajkumar
Leading myeloma specialist; chair of ECOG Myeloma Committee
Mayo Clinic
Episode: Episode 71. Management of Newly Diagnosed Multiple Myeloma with Dr. Vincent Rajkumar
Curtis Lachowiez
Assistant professor in the Division of Hematology and Medical Oncology
Oregon Health Sciences University
Episode: Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez
Carla Casulo
Associate Professor at the Wilmot Cancer Centre, University of Rochester, renowned lymphoma expert focusing on follicular lymphoma.
Wilmot Cancer Centre, University of Rochester
Episode: Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo
Dr. Luciano Costa
Myeloma investigator at the University of Alabama
University of Alabama, Birmingham
Episode: Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa
Michelle Yong
Associate Professor and CMV expert
Peter MacCallum Cancer Centre
Episode: Episode 67. Management of CMV in Hematologic Malignancies

Hosts

Raj Chakraborty
Host and moderator with Columbia University affiliation; leads conversations and shapes practical takeaways.
Ashwin Kishtagari
Co-host and hematology expert guiding discussions with clinical depth and regional perspectives.
Edward Cliff
Co-host bringing Harvard-affiliated perspective and clinical insights to discussions.

Reviews

4.9 out of 5 stars from 120 ratings
  • Wow

    What a truly incredible podcast. Dr. Chakraborty is really fantastic.

    Apple Podcasts
    5
    Ahhshhhhax
    United States2 years ago
  • 5 stars

    Phenomenal podcast. Very educational, comprehensive, *relevant* and easy to follow. Have begun sharing with colleagues in the community whose patients will significantly benefit from the knowledge and insights offered. Grateful to the creators and hosts.

    Apple Podcasts
    5
    MT_2023
    United States2 years ago
  • Medicine as deep as our souls

    The episode with Dr. Azra Raza is so rich and healing. Thank you.

    Apple Podcasts
    5
    SheilaAstro
    United States2 years ago
  • Excellent format and extremely informative

    Very informative and great guest speakers from different institutions, high clinical yield.

    Apple Podcasts
    5
    Sassine Ghanem
    United States2 years ago
  • The Best among the Best! Thank you all!

    Please keep going…! Thank you creator!

    Apple Podcasts
    5
    Summer35!
    United States3 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Shows high-quality clinical insights from top hematology experts.
Guests are well-chosen and topics are timely and relevant to practice.
Content is educational, rigorous, and consistently well-produced.
Listeners appreciate practical takeaways and expert context on trials.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#111
Brazil/Education

Talking Points

Recent interactions between the hosts and their guests.

Episode 75. ASCO & EHA 2026 Myeloid Roundup with Dr. Joshua Zeidner
Q: How should clinicians interpret the EFS results in light of OS crossover and the lack of statistical OS difference between arms?
EFS differences appear convincing, but crossovers and heterogeneous timing of events cloud OS interpretation; regulators and clinicians should view EFS as informative but still rely on OS and long-term follow-up when advising practice, especially since crossovers can mask potential survival advantages.
Episode 75. ASCO & EHA 2026 Myeloid Roundup with Dr. Joshua Zeidner
Q: Curtis, what are your initial thoughts on Paradigm as an IIT and its overall design given the strict inclusion criteria and long enrollment period?
The study is a remarkable demonstration of a multi-center IIT with randomized phase II design, showing thoughtful inclusion that targets younger, fit patients while balancing subtypes to avoid those with markedly different treatment paths; however, the accessibility of enrollment and the selective population raise questions about generalizability to all AML patients.
Episode 74. Myeloma Updates from ASCO/EHA 2026 with Dr. Prashant Kapoor
Q: Dr. Kapoor, can you summarize the primary outcomes of MajesTEC-3 and how these results might apply to patients at first or second relapse?
MajesTEC-3 showed a dramatic improvement in progression-free survival with Tec-Dara compared to DPD/DVD, with very favorable long-term outcomes and a notable separation in survival curves, suggesting these T-cell engaging therapies can extend benefit even in patients with prior lines of therapy and potentially be applicable to earlier relapse settings depending on patient-specific factors.
Episode 71. Management of Newly Diagnosed Multiple Myeloma with Dr. Vincent Rajkumar
Q: How do you view the role of MRD testing in transplant decisions and maintenance strategies?
MRD testing is informative but not the sole determinant for transplant timing; fixed induction followed by transplant remains a common approach, and decisions about MRD-directed transplant are still evolving. In maintenance, MRD status contributes to tailoring whether doublet maintenance or single-agent maintenance is appropriate, but duration and cost considerations are also critical.
Episode 71. Management of Newly Diagnosed Multiple Myeloma with Dr. Vincent Rajkumar
Q: What are your thoughts on when to perform a kidney biopsy or how to handle suspected myeloma cast nephropathy in the setting of high creatinine and high free light chains?
In suspected cast nephropathy, you should pursue rapid disease control with effective anti-myeloma therapy and consider plasma exchange where available, especially with very high light chains, though some settings can manage without exchange if the patient rapidly improves on therapy. Kidney biopsy is reserved for unclear cases where alternative etiologies are suspected or when light-chain burden is not clearly driving the injury.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Blood Cancer Talks

What is Blood Cancer Talks about and what kind of topics does it cover?

A compact, expert-led show that mines the latest hematology research and clinical practice through conversations with leading clinicians and researchers. Episodes routinely cover new data from major meetings (ASCO, EHA, ASH), emerging therapies (bispecifics, CAR-T, novel antibodies), and practical considerations for real-world care—risk stratification, treatment sequencing, CNS prophylaxis, and management of infection and toxicities. A standout pattern is in-depth analysis from renowned cancer centers, with an emphasis on translating abstract trial results into actionable guidance for hematologists treating lymphoma, myeloma, AML, and related blood cancers. The format tends to be data-forward, with careful scrutiny of trial design, endpoint... more

Where can I find podcast stats for Blood Cancer Talks?

Rephonic provides a wide range of podcast stats for Blood Cancer Talks. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Blood Cancer Talks and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Blood Cancer Talks get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for Blood Cancer Talks, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Blood Cancer Talks?

Rephonic provides comprehensive predictive audience data for Blood Cancer Talks, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Blood Cancer Talks have?

To see how many followers or subscribers Blood Cancer Talks has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Blood Cancer Talks?

These podcasts share a similar audience with Blood Cancer Talks:

1. WolverHeme Happy Hour
2. Two Onc Docs
3. Blood Podcast
4. Hematologic Oncology Update
5. VJHemOnc Podcast

How many episodes of Blood Cancer Talks are there?

Blood Cancer Talks launched 4 years ago and published 76 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Blood Cancer Talks?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Blood Cancer Talks?

Rephonic pulls ratings and reviews for Blood Cancer Talks from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Blood Cancer Talks?

Rephonic provides full transcripts for episodes of Blood Cancer Talks. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Blood Cancer Talks?

Recent guests on Blood Cancer Talks include:

1. Curtis Lacovitz
2. Prashant Kapoor
3. Thomas Lew
4. Charles Herbaux
5. Vincent Rajkumar
6. Curtis Lachowiez
7. Carla Casulo
8. Dr. Luciano Costa

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days